McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity.

Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization. BMC Infect Dis (2017) 0.75

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66

Multiple sclerosis. Lancet (2002) 7.11

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet (2009) 4.16

MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47

Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology (2007) 2.47

The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology (2003) 2.35

Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol (2000) 2.10

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry (1994) 1.98

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler (2015) 1.72

Clinically isolated syndromes. Lancet Neurol (2012) 1.59

Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol (2006) 1.54

Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler (1998) 1.33

External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem (1995) 1.32

CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry (2008) 1.32

Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22

Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry (2013) 1.19

Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain (2015) 1.08

A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 1.02

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01

Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol (2013) 0.90

Importance of follow-up cerebrospinal fluid analysis in cryptococcal meningoencephalitis. Dis Markers (2014) 0.89

The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J Neuroimmunol (2010) 0.84